Houston-based Vertex Energy Inc . (OTC Pink:OTC:VTNRQ), a petroleum refining company with annual revenues of $3.2 billion, has received confirmation from the U.S. Bankruptcy Court for the Southern ...

VX-407 is under clinical development by Vertex Pharmaceuticals and currently in Phase I for Polycystic Kidney Disease. According to GlobalData, Phase I drugs for Polycystic Kidney Disease have a 69% ...

Industry Standard restaurant is finally set to open in the former Carly's Bistro space in downtown Phoenix. Carly's Bistro, a Roosevelt Row staple for nearly 20 years, closed in May in May when ...

Animation Baker and Instancing for Animated Characters: Using GPU to implement large-amount animation characters rendering. The animation map for vertex shader to modify the vertex position of the ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...

Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue ...

As per the data shared, 47 incidents of violence against Hindus were reported in Bangladesh in the year 2022, 302 in 2023 and surged to 2,200 in 2024 (till December 8, 2024). In Pakistan, 241 cases of ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...

The deployment of the dragon drone technology comes as Kyiv claimed to have killed 2,200 Kremlin troops in a single day according to latest figures. Despite the mounting dead, Russian President ...

Russia has suffered its deadliest day of the war so far with more than 2,200 troops killed over the ... Ukrainian news outlet Ukrainska Pravda. The Standard could not independently verify the ...

JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which ...